BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
367 results:

  • 1. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
    Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes.
    Thangavel SK; Mohamed Kasim MS; Rengan R
    Inorg Chem; 2024 Apr; 63(16):7520-7539. PubMed ID: 38590210
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. erbb2/her2 receptor tyrosine kinase regulates human papillomavirus promoter activity.
    Mikuličić S; Shamun M; Massenberg A; Franke AL; Freitag K; Döring T; Strunk J; Tenzer S; Lang T; Florin L
    Front Immunol; 2024; 15():1335302. PubMed ID: 38370412
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
    Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
    Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [A Case of Breast cancer Complicated by Fibrous Dysplasia That Was Difficult to Differentiate from Bone Metastasis].
    Makino Y; Otani A; Hikino H; Murata Y; Miura H; Harada A
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1465-1467. PubMed ID: 38303309
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [A Long-Term Survival Case of her2-Positive Gastric cancer with Distant Lymph Node Metastasis Receiving Multidisciplinary Therapy].
    Yasuoka S; Urakawa S; Kato J; Kidogami S; Fukata T; Nishida H; Ohigashi H; Takemoto H; Fukuzaki T
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1816-1818. PubMed ID: 38303217
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
    Chen J; Pang L; He L; Li T; Cheng X
    Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeting her2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
    Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Antibody-Drug Conjugates in Gynecologic cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular landscape of erbb2/her2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
    Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Characteristics of HPV integration in cervical adenocarcinoma and squamous carcinoma.
    Bi Y; Hu J; Zeng L; Chen G; Cai H; Cao H; Ma Q; Wu X
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17973-17986. PubMed ID: 37966613
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Antibody-Drug Conjugates (ADC) in her2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer.
    Lin Y; Yang Q
    Anticancer Drugs; 2024 Feb; 35(2):209-217. PubMed ID: 37948339
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The value of multiparametric MRI combined with clinical prognostic parameters in predicting the 5-year survival of stage IIIC1 cervical squamous cell carcinoma.
    Qin F; Pang H; Ma J; Xu H; Yu T; Luo Y; Dong Y
    Eur J Radiol; 2023 Dec; 169():111181. PubMed ID: 37939604
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma.
    Lin S; Sun Y; Cao C; Zhu Z; Xu Y; Liu B; Hu B; Peng T; Zhi W; Xu M; Ding W; Ren F; Ma D; Li G; Wu P
    EBioMedicine; 2023 Nov; 97():104846. PubMed ID: 37879219
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
    J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
    Yao Y; Wang Y; Ye L; Lu B; Lu W
    Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
    Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
    J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The role of sialylation in gynecologic cancers.
    Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
    Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 19.